BCA
CBIO

Berman Capital Advisors’s Crescent Biopharma CBIO Stock Holding History

Berman Capital Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11
Closed -$3K – 1951
2021
Q1 		$3K Sell
11
-1
-8% -$358 ﹤0.01% 1416
2020
Q4 		$4K Hold
12
– – ﹤0.01% 1218
2020
Q3 		$3K Hold
12
– – ﹤0.01% 1191
2020
Q2 		$4K Buy
+12
New +$3.4K ﹤0.01% 1052

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Berman Capital Advisors's CBIO Position: Q2 2021 in Review

Berman Capital Advisors sold out of Crescent Biopharma (CBIO) in Q2 2021, closing a stake of 11 shares — an estimated $3K sold.

Berman Capital Advisors first reported a position in CBIO in Q2 2020 and held it in 4 quarters. The position peaked at $4K in Q4 2020. 58 funds tracked by Wall St. Rank hold CBIO as of Q2 2021.

  • Berman Capital Advisors reported no remaining Crescent Biopharma position as of Q2 2021 after selling out during the quarter.
  • Berman Capital Advisors sold 11 Crescent Biopharma shares in Q2 2021, an estimated $3K.
  • Berman Capital Advisors first reported a position in Crescent Biopharma in Q2 2020 and held it in 4 quarters.
  • Berman Capital Advisors's Crescent Biopharma position peaked at $4K in Q4 2020.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2021.

Based on Berman Capital Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.